General Announcement::Glenmark Pharmaceuticals Announces Exclusive Licensing Agreement with Seqirus

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
06-Jul-2018 12:21:08
Status
New
Announcement Sub Title
Glenmark Pharmaceuticals Announces Exclusive Licensing Agreement with Seqirus
Announcement Reference
SG180706OTHR1JBV
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
06/07/2018 09:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals Announces Exclusive Licensing Agreement with Seqirus for its Investigational Seasonal Allergic Rhinitis Nasal Spray Ryaltris for Australia and New Zealand Markets

Attachments

PR_06072018.pdf
Total size =3298K